NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Sept. 3, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Calico announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer.
Calico is the Google-backed life sciences company that is led by Arthur D. Levinson Ph.D. (former chairman and CEO of Genentech) and Hal V. Barron, M.D. (former Executive Vice President and Chief Medical Officer of Genentech). The agreement paves the way for Calico to establish a world-class research and development facility in the San Francisco Bay Area.
Under the agreement, the companies will combine their complementary strengths to accelerate the availability of new therapies for age-related diseases:
"This collaboration demonstrates our commitment to exploring new areas of medicine and innovative approaches to drug discovery and development that augments our already robust pipeline," said Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer, AbbVie. "We are pleased to be working with such outstanding scientists as Art Levinson, Hal Barron and their team. The potential to help improve patients' lives with new therapies is enormous."
"Our relationship with AbbVie is a pi
Copyright©2014 PR Newswire.
All rights reserved